More information: Sergio Escamilla et al, Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients, Alzheimer's & Dementia (2024). DOI: 10.1002/alz.14125 ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue.

it’s known as early onset Alzheimer’s disease (EOAD). Memantine is an NMDA receptor antagonist. These medications work by blocking N-methyl-D-aspartate (NMDA) receptors and reducing excess ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 ...

Samantha Schwarz, a doctoral candidate in the neuroscience program, won the second place prize of $1,500 in UB’s ninth annual Three Minute Thesis (3MT) competition.

AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor under development for the ...